 |
| Global Orphan Drugs Market |
The
drugs which are developed for treatment of rare diseases and
conditions are referred to as orphan
drugs. The rare diseases such as Tourette syndrome,
Huntington’s disease, muscular dystrophy, myoclonus, and ALS (Lou
Gehrig’s disease) are some of those diseases for treatment of which
adequate drugs have not been developed, and hence these diseases are
treated by orphan drugs. Orphan drugs are developed by the
pharmaceutical companies for public health need, and the sales
generated by this drugs are very minimal when compared to normal
drugs. The orphan diseases manifest in patient populations
representing 6-8% of the global population. Symptoms of some orphan
diseases may appear at birth or in childhood including cystic
fibrosis, infantile spinal muscular atrophy, familial adenomatous
polyposis (FAP), and some others.
Request
For Sample Copy Of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/500
Developing
novel indications for designated orphan drugs is expected to drive
the orphan drugs market
There
are around 5,000 rare diseases listed globally and 80% of those are
to genetic origins. The probability of getting infected by these
diseases in adults is 50%.The need for the development of orphan
drugs which will treat such diseases and proactive initiatives
undertaken by government and regulatory authorities are the major
factors driving the orphan drugs market. For instance, the
authorities of U.S. FDA for orphan drug development department are
providing the incentives to healthcare and biotechnology industries
in order to enhance their research and development in orphan drugs.
There are few drugs that have been withdrawn from the market due to
certain risk developed over prolong administration of these drugs.
However, these drugs have shown good results for treatment of those
diseases which in particular do not have any standard drug, owing to
drive the orphan drugs market. For instance, thalidomide used as a
hypnotic drug was withdrawn from market when teratogenic risk was
discovered, however, this drug has shown prominent result in treating
leprosy.
Numerous
collaborative research programs across North America and Europe is
owing to growth of orphan drugs market
Regional
segmentation of orphan drugs market by Coherent Market Insights
comprises of North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa. North America dominates the market globally
due to factors such as established regulatory and reimbursement
framework and incentives given by U.S. Food and Drug Administration
(FDA) for research and development in orphan drugs sector. The
various collaborative research programs across United States and
Europe provides research data on rare diseases to manufacturers,
patients and health experts which gives timely medical care, thus
boost the orphan drug market. Whereas the prevalence of genetic
diseases and growth of population are some factors which might allow
the orphan drugs manufacturers to invest in the Asia Pacific region.
Initiatives
taken by government to increase the investment in orphan drugs
development driving the growth of orphan drugs market.
Key
players operating the orphan drugs market are Acorda Therapeutics,
Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter
international, Bayer healthcare pharmaceuticals, Biomarin
Pharmaceuticals, Novartis, F.Hoffmann-La Roche AG, Johnson and
Johnson and many others. The increase in investments, and some
initiatives taken by government helping the orphan drug
manufacturers. For instance, U.S. government provides 50% of tax
credit on the research and development expenses spent on the orphan
drugs development by manufacturers. However the high cost of the
orphan drugs and generation of small sales from it is amongst those
factors which is lowering the interest of companies for market.
The
increasing prevalence of rare cancer in patients owing to oncological
diseases segment to dominate in the orphan drugs market
The
global orphan drugs market is segmented on the basis of disease, by
product type and by region
On
The Basis Of Disease Type:
•
Hematologic and Immunologic diseases
•
Infectious diseases
•
Metabolic diseases
•
Neurologic diseases
•
Oncologic diseases
•
Other orphan diseases
On
The Basis Of Product Type:
•
Biological orphan drugs
•
Non-biological orphan drugs
Request
For Discount of This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/500
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
0 comments:
Post a Comment